# Muscle Preservation During Caloric Restriction: Research Compound Insights Evidence & Research Status Evidence LevelExtensive Human Clinical Data FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO) — not for human consumption Last UpdatedAugust 5, 2026 What This Article Covers Caloric restriction reliably reduces total body mass. Without specific countermeasures, it also reliably reduces some of that mass from skeletal muscle. This is not unique to any pharmacological… Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use. *For research and educational purposes only. All compounds discussed are sold as research chemicals, not for human use or consumption.* Key Takeaways - Caloric restriction research consistently reports some degree of lean mass loss alongside fat loss. - Clinical trials quantify how much lean mass is typically lost under different restriction regimens. - Resistance training and protein intake remain the most well-established co-interventions. - Several research compounds are studied specifically for their potential role in lean mass preservation. ## The Lean Mass Problem in Caloric Restriction Research Caloric restriction reliably reduces total body mass. Without specific countermeasures, it also reliably reduces some of that mass from skeletal muscle. This is not unique to any pharmacological intervention — it is a well-documented consequence of energy deficit itself. The body under caloric restriction draws on both adipose tissue and protein stores (including muscle) for fuel, governed by hormonal signals including insulin, cortisol, and IGF-1. The clinical significance of lean mass loss during weight reduction is substantial. Skeletal muscle is the primary site of glucose disposal, the largest contributor to resting metabolic rate, and a determinant of long-term functional capacity. Loss of lean mass during a weight-loss intervention increases the risk of weight regain after discontinuation and can accelerate age-related sarcopenia. For researchers studying compounds that produce significant caloric restriction through appetite modulation — particularly GLP-1 receptor agonists — understanding and addressing lean mass loss has become a central focus. ## Magnitude of Lean Mass Loss: What Clinical Trials Report Published body composition sub-studies from major GLP-1 trials establish the baseline. In the STEP 1 trial (semaglutide 2.4mg), participants lost a mean of 15.3kg total. Approximately 38% of that loss was fat-free mass — roughly 5.8kg. SURMOUNT-1 (tirzepatide) showed similar patterns: DEXA sub-studies indicated fat-free mass constituted roughly 30–37% of total weight lost, varying by dose. Comparison arms using lifestyle intervention alone showed similar fat-free mass loss percentages at equivalent total weight loss, supporting the conclusion that the lean mass effect is deficit-driven rather than compound-specific. ## Resistance Training and Protein: The Most Established Co-Interventions **Dietary protein sufficiency** at approximately 1.2–1.6g per kilogram of body weight is consistently associated with better lean mass retention during caloric restriction across multiple RCTs. Protein provides amino acid substrates for muscle protein synthesis and has a higher thermic effect than carbohydrates or fat. **Resistance training** generates a potent anabolic signal independent of caloric status. Multiple studies demonstrate that resistance training during caloric restriction significantly attenuates lean mass loss — and in some populations can produce net lean mass gains even during a deficit. The combination of high protein intake plus resistance training consistently outperforms either intervention alone. ## Research Compounds of Interest for Lean Mass Preservation ### Amylin Receptor Agonists (Cagrilintide) [Cagrilintide](https://portaltowellness.net/shop/cagrilintide/) , an amylin analog studied in combination with semaglutide, shows preliminary compositional data suggesting the combination may produce a lower proportion of lean mass loss compared to semaglutide monotherapy at equivalent total weight reduction. The proposed mechanism involves complementary appetite-modulating pathways that may allow equivalent caloric restriction at lower effective doses of GLP-1 agonism. ### MOTS-c and Mitochondrial Peptides [MOTS-c](https://portaltowellness.net/shop/mots-c-40mg-vial/) is a mitochondrial-derived peptide studied for effects on cellular energy metabolism. Preclinical studies show it activates AMPK, improves insulin sensitivity in skeletal muscle, and may support mitochondrial biogenesis. Muscle tissue that is metabolically active and insulin-sensitive is more likely to be preserved under caloric deficit than tissue with impaired substrate utilization. Human studies are underway. ### BPC-157 and Recovery Compounds [BPC-157](https://portaltowellness.net/shop/bpc-157-tb-500-injectable/) is studied primarily for tissue repair and recovery. Research into its effects on muscle healing and growth factor signaling (particularly VEGF) has generated interest in whether it may support recovery from resistance training — which would have indirect relevance for maintaining the exercise stimulus needed to preserve lean tissue during a caloric deficit. ### Triple Agonists and Lean Mass: The Retatrutide Question Retatrutide‘s glucagon receptor component increases energy expenditure and promotes fat oxidation from hepatic and visceral stores. Researchers are investigating whether this shifts the composition of weight lost toward a higher fat proportion. Phase 3 compositional data will be informative. ## Combining Interventions in Published Trials Research Watch — August 7, 2026 A randomized trial from William Marsh Rice University and The Methodist Hospital Research Institute (NCT07554417) is testing whether a 12-week supervised resistance-and-aerobic exercise program plus individualized dietary counseling preserves skeletal muscle mass and bone mineral density (measured by DEXA) in adults on semaglutide, compared with semaglutide alone. Estimated study completion is August 2026; no results have been posted yet. Worth revisiting once findings are published — it is one of the few prospective, randomized studies designed specifically to test a lifestyle-intervention countermeasure to GLP-1-associated muscle loss, rather than observing it after the fact. Research Watch — August 8, 2026 Veru Inc.’s Phase 2b PLATEAU trial completed enrollment on July 27, 2026: roughly 200 adults 65 and older with obesity, starting semaglutide, randomized to enobosarm 3mg or placebo. Researchers are tracking total body weight, fat mass, lean mass, physical function, and bone mineral density (DXA) through 68 weeks, with an interim lean-mass/fat-mass readout expected in Q1 2027 and final topline data in Q4 2027 — over a year out, not imminent. It is one of the first placebo-controlled trials testing whether an added compound can specifically preserve lean mass and function during GLP-1-driven weight loss in an older population, rather than relying on exercise/nutrition alone as the countermeasure. No efficacy data yet; nothing here should be read as evidence enobosarm works. ## Related Research at Portal to Wellness - [Body Recomposition with GLP-1 Peptides: What the Research Shows](https://portaltowellness.net/research/body-recomposition-glp1-research/) - [Visceral Fat and Metabolic Health: What Researchers Are Studying](https://portaltowellness.net/research/visceral-fat-metabolic-health-research/) - [MOTS-c: The Mitochondrial-Derived Peptide Explained](https://portaltowellness.net/research/mots-c-mitochondrial-peptide-research/) - [Recovery & Repair Research Compounds: A Complete Guide](https://portaltowellness.net/research/recovery-repair-research-compounds-guide/) - [Metabolic Research Compounds](https://portaltowellness.net/product-category/metabolic-research/) 📚 Part of our [Metabolic](https://portaltowellness.net/metabolic-optimization-kit/) research guide. Available at PTW PTW Creatine + Hydration — Daily Support Powder [Shop Creatine + Hydration →](https://portaltowellness.net/shop/ptw-creatine-hydration-daily-support-powder/) ### Continue Your Research Related Articles [Weight Loss vs. Body Composition: Why Muscle Matters During GLP-1 Research](https://portaltowellness.net/research/weight-loss-vs-body-composition-glp1-muscle/) [Wegovy Pill Total Monthly Cost, Explained](https://portaltowellness.net/research/wegovy-pill-total-monthly-cost/) Related Products [PTW Daily Essentials Kit — Creatine, Electrolytes and Magnesium](https://portaltowellness.net/shop/ptw-daily-essentials-kit/) [PTW Creatine + Hydration — Daily Support Powder](https://portaltowellness.net/shop/ptw-creatine-hydration-daily-support-powder/) [Semaglutide – 5mg/vial — Research Use Only](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/) Related Research Guide [GLP-1 & Metabolic Research Guide](https://portaltowellness.net/metabolic-research-kit/) Related Category [GLP-1 & Metabolic Research Guide](https://portaltowellness.net/metabolic-research-kit/) Related FAQ [General Research & Ordering FAQ](https://portaltowellness.net/faq/) More Research [Browse the full PTW Research Hub →](https://portaltowellness.net/research/) --- Source: https://portaltowellness.net/research/muscle-preservation-caloric-restriction-research/ Research use only. Terms: https://portaltowellness.net/research-use-only/